Adjuvant mitoxantrone + prednisone + ADT in treatment of high-risk prostate cancer

About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …

Let’s prove the obvious all over again

Once again your sitemaster finds himself flabbergasted at just how often we need to repeat similar experiments to prove the obvious. … READ MORE …

More information about how BAT may work

We know that “cycling” prostate cancer patients on and off high doses on testosterone while they are on androgen deprivation therapy (ADT) appears to have significant therapeutic benefit in at least some patients (see, for example, here). … READ MORE …

Mental health and ADT: an objective review

As regular readers will be aware, there has been some intense debate over the past year or so about whether there is an association between treatment with androgen deprivation therapy (ADT) and risk for dementia. … READ MORE …

Low PSA levels on ADT do correlate to longer survival times

For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”)  have significant predictive impact on long-term survival. … READ MORE …

When can ADT be safely avoided with salvage radiation therapy?

Two randomized clinical trials (GETUG-AFU-16 and RTOG 9601) proved that adding at least some ADT to salvage radiation (SRT) improved outcomes. “Some ADT” was 6 months of goserelin acetate in the GETUG-AFU-16 trial, and 2 years of bicalutamide in the RTOG 9601 trial. … READ MORE …

BAT + enzalutamide: data from the RESTORE study

Just over a year ago we wrote up a commentary on this web site entitled, “Can bipolar cycling of testosterone really cure prostate cancer?” It dealt with what is known as “bipolar androgen therapy” or BAT and referred to a Phase II clinical trial known as the RESTORE study. … READ MORE …